Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
silberip
- Development stage
- Unknown
- Lead developer
- Currax Pharmaceuticals
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
"Silberip" is not a recognized pharmaceutical agent and appears to be a non-existent drug name resulting from a corrupted data extraction or OCR error of Currax Pharmaceuticals' product pipeline. According to the provided context, it is described as a marketed treatment for sleep disorders containing the active ingredient pramlintide. However, this entry is factually incorrect; Currax markets **Silenor** (doxepin) for the treatment of insomnia (sleep) and **Symlin** (pramlintide) for the management of type 1 and type 2 diabetes. Pramlintide is a synthetic amylin analog that regulates postprandial glucose levels and is not indicated for sleep disorders. The name "silberip" likely stems from a misreading of "Silenor" combined with the ingredient description of "Symlin" in a tabular pipeline format.
- Brand names
- Silberip
- Other names
- pramlintide
02
Targets
AMY receptor (Calcitonin receptor (with ramps))RAMP2 (Receptor activity-modifying protein 2)RAMP1 (Receptor activity-modifying protein 1)CALCR (Calcitonin receptor)RAMP3 (Receptor activity-modifying protein 3)
Beyond the preview
Go deeper on silberip.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on silberip.